Exceptional Response of BRAF^V600E-Mutated Acinar Cell CUP to BRAF/MEK Inhibition

Affiliations

• ¹ Department for Translational Medical Oncology, National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
• ² Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
• ³ German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany.
• ⁴ Department of Medicine 2, University Cancer Center Leipzig (UCCL), Leipzig University Medical Center, Cancer Center Central Germany (CCCG), Leipzig, Germany.
• ⁵ Institute of Pathology, Leipzig University Medical Center, Leipzig, Germany.
• ⁶ Department of Nuclear Medicine, Leipzig University Medical Center, Leipzig, Germany.
• ⁷ Core Unit for Molecular Tumor Diagnostics (CMTD), National Center for Tumor Diseases Dresden (NCT/UCC), Dresden, Germany.
• ⁸ German Cancer Research Center (DKFZ), Heidelberg, Germany.
• ⁹ Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
• ¹⁰ Institute for Clinical Genetics, University Hospital Carl Gustav Carus at TU Dresden, Dresden, Germany.
• ¹¹ ERN GENTURIS, Hereditary Cancer Syndrome Center Dresden, Dresden, Germany.
• ¹² Institute of Pathology, Carl Gustav Carus University Hospital, Dresden, Germany.
• ¹³ German Cancer Research Center (DKFZ) Heidelberg, Translational Functional Cancer Genomics, Heidelberg, Germany.